Gut–liver axis, cirrhosis and portal hypertension: the chicken and the egg
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
The term gut–liver axis is used to highlight the close anatomical and functional relationship between the intestine and the liver. The intestine has a highly specialized epithelial membrane which regulates transport across the mucosa. Due to dysbiosis, impairment of the intestinal barrier and altered immunity status, bacterial products can reach the liver through the portal vein, where they are recognized by specific receptors, activate the immune system and lead to a proinflammatory response. Gut microbiota and bacterial translocation play an important role in the pathogenesis of chronic liver diseases, including alcoholic and non-alcoholic fatty liver disease, cirrhosis, and its complications, such as portal hypertension, spontaneous bacterial peritonitis and hepatic encephalopaty. The gut microbiota also plays a critical role as a modulator of bile acid metabolism which can also influence intestinal permeability and portal hypertension through the farnesoid-X receptor. On the other hand, cirrhosis and portal hypertension affect the microbiota and increase translocation, leading to a “chicken and egg” situation, where translocation increases portal pressure, and vice versa. A myriad of therapies targeting gut microbiota have been evaluated specifically in patients with chronic liver disease. Further studies targeting intestinal microbiota and its possible hemodynamic and metabolic effects are needed. This review summarizes the current knowledge about the role of gut microbiota in the pathogenesis of chronic liver diseases and portal hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
Martinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066 · cited 1×
“Activation of NLRs results in the up-regulation of cytokines and chemokines, such as IL-1b and IL-18, which are then released to recruit and activate additional inflammatory cells [63, 64].”
Sterile inflammation: sensing and reacting to damage
Chen, G. Y., & Nuñez, G. (2010) · Nature Reviews Immunology · doi:10.1038/nri2873 · Cited by 3,051 · cited 1×
“This may lead to sterile inflammation and plays a role in the pathogenesis of non-alcoholic and alcoholic liver disease [49, 60].”
The Inflammasomes: Guardians of the Body
Martinon, F., Mayor, A., & Tschopp, J. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132715 · Cited by 2,436 · cited 8×
“DAMPS may also activate NLRs which regulate inflammatory and apoptotic responses along with TLRs [61, 62].”
InfluentialInflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435 · cited 1×
“Dysbiosis, defined as the imbalance between protective and harmful bacteria, and the alteration of intestinal barrier may also influence the degree of hepatic steatosis, inflammation and fibrosis through multiple interactions with the host’s immune system and other cell types [7].”
Agostini, L., Martinon, F., Burns, K., McDermott, M. F., Hawkins, P. N., & Tschopp, J. (2004) · Immunity · doi:10.1016/s1074-7613(04)00046-9 · Cited by 1,768
Boursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo‐Perez, F., Guy, C. D., Seed, P. C., Rawls, J. F., David, L. A., et al. (2016) · Hepatology · doi:10.1002/hep.28356 · Cited by 1,483
Bile acids and the gut microbiome
Ridlon, J. M., Kang, D. J., Hylemon, P. B., & Bajaj, J. S. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000057 · Cited by 1,329 · cited 1×
“The gut microbiota also plays a critical role as modulator of bile acids (BAs) pool size and composition, through defined enzymatic activities (dihydroxylation, oxidation and epimerization among others), and significantly modifying the signaling properties of BAs and their actions on BA receptors [22, 72, 73].”
Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor
Inagaki, T., Moschetta, A., Lee, Y.-K., Peng, L., Zhao, G., Downes, M., Yu, R. T., Shelton, J. M., Richardson, J. A., Repa, J. J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509592103 · Cited by 1,164 · cited 1×
“BAs mediate the absorption of dietary lipids but also play a pivotal role contributing to select intestinal microbiome [74] by means of their direct antimicrobial effects through the farnesoid-X receptor (FXR)-induced production of antimicrobial peptides such as angogenin1 and RNase family member 4 [75, 76].”
Altered profile of human gut microbiome is associated with cirrhosis and its complications
Bajaj, J. S., Heuman, D. M., Hylemon, P. B., Sanyal, A. J., White, M. B., Monteith, P., Noble, N. A., Unser, A. B., Daita, K., Fisher, A. R., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.019 · Cited by 1,099 · cited 1×
“Ruminococcaceae [31] Proteobacteria (Enterobacteriaceae) [30]”
Characterization of fecal microbial communities in patients with liver cirrhosis
Chen, Y., Yang, F., Lu, H., Wang, B., Chen, Y., Lei, D., Wang, Y., Zhu, B., & Li, L. (2011) · Hepatology · doi:10.1002/hep.24423 · Cited by 1,038
Johansson, M. E. V., Gustafsson, J. K., Holmén-Larsson, J., Jabbar, K. S., Xia, L., Xu, H., Ghishan, F. K., Carvalho, F. A., Gewirtz, A. T., Sjövall, H., et al. (2014) · Gut · doi:10.1136/gutjnl-2012-303207 · Cited by 1,004 · cited 1×
“The luminal mucus layer prevents large particles and intact bacteria from coming into contact with the epithelium [12].”
Crispe, I. N. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132629 · Cited by 986 · cited 2×
“TLRs are transmembrane proteins that play a key role in the innate immune system, usually expressed in sentinel cells such as macrophages and dendritic cells; however, TLRs have been identified in response to LPS of hepatic non-immune cells, including hepatic stellate cells and endothelial cells [38, 48].”
Levy, M., Thaiss, C. A., Zeevi, D., Dohnalová, L., Zilberman-Schapira, G., Mahdi, J. A., David, E., Savidor, A., Korem, T., Herzig, Y., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.048 · Cited by 960
Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013
Jalan, R., Fernandez, J., Wiest, R., Schnabl, B., Moreau, R., Angeli, P., Stadlbauer, V., Gustot, T., Bernardi, M., Canton, R., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.024 · Cited by 906
Proton pump inhibitors alter the composition of the gut microbiota
Jackson, M. A., Goodrich, J. K., Maxan, M.-E., Freedberg, D. E., Abrams, J. A., Poole, A. C., Sutter, J. L., Welter, D., Ley, R. E., Bell, J. T., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310861 · Cited by 895
Gadaleta, R. M., van Erpecum, K. J., Oldenburg, B., Willemsen, E. C. L., Renooij, W., Murzilli, S., Klomp, L. W. J., Siersema, P. D., Schipper, M. E. I., Danese, S., et al. (2011) · Gut · doi:10.1136/gut.2010.212159 · Cited by 870 · cited 1×
“On the other hand, it has been described that FXR activation markedly inhibits inflammation and preserves the intestinal barrier function reducing bacterial translocation in inflammatory bowel disease [80] and in a rat model of cholestatic liver injury [81] (Fig.”
Gut–Liver Axis in Alcoholic Liver Disease
Szabo, G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.10.042 · Cited by 754
Toll‐like receptors and adaptor molecules in liver disease: Update†
Seki, E., & Brenner, D. A. (2008) · Hepatology · doi:10.1002/hep.22306 · Cited by 722 · cited 3×
“TLRs are transmembrane proteins that play a key role in the innate immune system, usually expressed in sentinel cells such as macrophages and dendritic cells; however, TLRs have been identified in response to LPS of hepatic non-immune cells, including hepatic stellate cells and endothelial cells [38, 48].”
Antibiotics prevent liver injury in rats following long-term exposure to ethanol
Adachi, Y., Moore, L. E., Bradford, B. U., Gao, W., & Thurman, R. G. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90027-6 · Cited by 692 · cited 2×
“This mechanism is especially relevant in alcoholic liver disease [67, 68], where studies in animal models have shown that the use of antibiotics or Kupffer cells elimination can alleviate alcohol-induced liver injury [69, 70].”
Bacterial translocation (BT) in cirrhosis†
Wiest, R., & Garcia‐Tsao, G. (2005) · Hepatology · doi:10.1002/hep.20632 · Cited by 677 · cited 1×
“In addition, intestinal bacterial overgrowth and changes in the composition of intestinal bacterial flora can promote bacterial translocation, defined as the migration of bacteria or bacterial products from the gut to the extra-intestinal space [27] (Fig.”
Parlesak, A., Schäfer, C., Schütz, T., Bode, J. C., & Bode, C. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80242-1 · Cited by 647
Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
Arab, J. P., Karpen, S. J., Dawson, P. A., Arrese, M., & Trauner, M. (2017) · Hepatology · doi:10.1002/hep.28709 · Cited by 634 · cited 2×
“Several studies on germ-free and FXR-deficient mice have shown that the gut microbiota also modulates BA profiles and influences FXR signaling [22, 79].”
Self-citationLinkage of gut microbiome with cognition in hepatic encephalopathy
Bajaj, J. S., Ridlon, J. M., Hylemon, P. B., Thacker, L. R., Heuman, D. M., Smith, S., Sikaroodi, M., & Gillevet, P. M. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00190.2011 · Cited by 547 · cited 1×
“treatment improves microbiota composition and function, clinical trials have not shown significant differences in those endpoints, probably due to these studies have been carried out in patients with advanced cirrhosis, and, therefore, the microbiota reflects the cirrhotic status rather than the effect of rifaximin [9…”
Bajaj, J. S., Heuman, D. M., Sanyal, A. J., Hylemon, P. B., Sterling, R. K., Stravitz, R. T., Fuchs, M., Ridlon, J. M., Daita, K., Monteith, P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060042 · Cited by 430 · cited 1×
“[96] showed that cirrhotic patients under rifaximin treatment, despite having a slight change in microbiota composition, have less Fig.”
Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD
Sabino, J., Vieira-Silva, S., Machiels, K., Joossens, M., Falony, G., Ballet, V., Ferrante, M., Van Assche, G., Van der Merwe, S., Vermeire, S., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-311004 · Cited by 413
Oxidative Stress and Alcoholic Liver Disease
Wu, D., & Cederbaum, A. (2009) · Seminars in Liver Disease · doi:10.1055/s-0029-1214370 · Cited by 342 · cited 1×
“In cirrhotic patients, due to a disrupted intestinal barrier, a greater influx of bacterial products to the liver occurs, leading to activation of liver immune cells and release of pro-inflammatory cytokines [65, 66].”
Dhiman, R. K., Rana, B., Agrawal, S., Garg, A., Chopra, M., Thumburu, K. K., Khattri, A., Malhotra, S., Duseja, A., & Chawla, Y. K. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.031 · Cited by 339
Lorenzo-Zúñiga, V., Bartolí, R., Planas, R., Hofmann, A. F., Viñado, B., Hagey, L. R., Hernández, J. M., Mañé, J., Alvarez, M. A., Ausina, V., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50116 · Cited by 321
Chen, P., Stärkel, P., Turner, J. R., Ho, S. B., & Schnabl, B. (2015) · Hepatology · doi:10.1002/hep.27489 · Cited by 312
Sandler, N. G., Koh, C., Roque, A., Eccleston, J. L., Siegel, R. B., Demino, M., Kleiner, D. E., Deeks, S. G., Liang, T. J., Heller, T., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.063 · Cited by 307
Al-Sadi, R., Ye, D., Boivin, M., Guo, S., Hashimi, M., Ereifej, L., & Ma, T. Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085345 · Cited by 280
Pérez-Paramo, M., Muñoz, J., Albillos, A., Freile, I., Portero, F., Santos, M., & Ortiz-Berrocal, J. (2000) · Hepatology · doi:10.1002/hep.510310109 · Cited by 271 · cited 1×
“In cirrhotic patients, treatment with NSBB has been shown to increase intestinal transit, reduce intestinal bacterial overgrowth, decrease intestinal permeability, and reduce bacterial translocation [92, 93].”
Verbeke, L., Farre, R., Trebicka, J., Komuta, M., Roskams, T., Klein, S., Elst, I. V., Windmolders, P., Vanuytsel, T., Nevens, F., et al. (2014) · Hepatology · doi:10.1002/hep.26939 · Cited by 258 · cited 1×
“pressure by lowering total intrahepatic vascular resistance without deleterious systemic hypotension [82].”
Non-alcoholic fatty liver and the gut microbiota
Bashiardes, S., Shapiro, H., Rozin, S., Shibolet, O., & Elinav, E. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.06.003 · Cited by 241
β‐Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta‐analysis
Senzolo, M., Cholongitas, E., Burra, P., Leandro, G., Thalheimer, U., Patch, D., & Burroughs, A. K. (2009) · Liver International · doi:10.1111/j.1478-3231.2009.02038.x · Cited by 241
Verbeke, L., Farre, R., Verbinnen, B., Covens, K., Vanuytsel, T., Verhaegen, J., Komuta, M., Roskams, T., Chatterjee, S., Annaert, P., et al. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.10.009 · Cited by 225 · cited 1×
“On the other hand, it has been described that FXR activation markedly inhibits inflammation and preserves the intestinal barrier function reducing bacterial translocation in inflammatory bowel disease [80] and in a rat model of cholestatic liver injury [81] (Fig.”
Tabibian, J. H., O'Hara, S. P., Trussoni, C. E., Tietz, P. S., Splinter, P. L., Mounajjed, T., Hagey, L. R., & LaRusso, N. F. (2016) · Hepatology · doi:10.1002/hep.27927 · Cited by 223 · cited 1×
“[47] have recently shown that the absence of the intestinal microbiota Bacterial transloca on Bacterial overgrowth Dysbiosis Tight junction disruption”
Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia
Bauer, T. M., Schwacha, H., Steinbruckner, B., Brinkmann, F. E., Ditzen, A. K., Aponte, J. J., Pelz, K., Berger, D., Kist, M., & Blum, H. E. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05791.x · Cited by 211 · cited 1×
“Small intestine bacterial overgrowth (SIBO) in cirrhotic patients has been demonstrated by quantitative analyses of bacterial cultures from jejunal aspirates [34].”
The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics
Ridlon, J. M., & Bajaj, J. S. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.01.006 · Cited by 210
Dam, G., Vilstrup, H., Watson, H., & Jepsen, P. (2016) · Hepatology · doi:10.1002/hep.28737 · Cited by 190 · cited 2×
“In two recent studies, PPI were identified as a risk factor for HE and SBP in patients with cirrhosis with ascites, with the risk increasing with dose [111, 113].”
Úbeda, M., Lario, M., Muñoz, L., Borrero, M.-J., Rodríguez-Serrano, M., Sánchez-Díaz, A.-M., del Campo, R., Lledó, L., Pastor, Ó., García-Bermejo, L., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.12.010 · Cited by 178
Toll-like Receptor 4 and Hepatic Fibrogenesis
Pradere, J.-P., Troeger, J., Dapito, D., Mencin, A., & Schwabe, R. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1255353 · Cited by 158
Bajaj, J. S., Cox, I. J., Betrapally, N. S., Heuman, D. M., Schubert, M. L., Ratneswaran, M., Hylemon, P. B., White, M. B., Daita, K., Noble, N. A., et al. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00268.2014 · Cited by 143
Dunagan, M., Chaudhry, K., Samak, G., & Rao, R. K. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00526.2011 · Cited by 103 · cited 1×
“showed that acetaldehyde mediates protein phosphatase 2A (PP2A) translocation to tight junctions and dephosphorylation of occludin on threonine residues [17].”
The unfolding web of innate immune dysregulation in alcoholic liver injury
Szabo, G., Mandrekar, P., Petrasek, J., & Catalano, D. (2011) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2010.01398.x · Cited by 82
Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis
Steib, C. J., Hartmann, A. C., Hesler, C. V., Benesic, A., Hennenberg, M., Bilzer, M., & Gerbes, A. L. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.60 · Cited by 54
Senzolo, M., Fries, W., Buda, A., Pizzuti, D., Nadal, E., Sturniolo, G. C., Burroughs, A. K., & DʼIncà, R. (2009) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.457 · Cited by 36 · cited 1×
“In cirrhotic patients, treatment with NSBB has been shown to increase intestinal transit, reduce intestinal bacterial overgrowth, decrease intestinal permeability, and reduce bacterial translocation [92, 93].”
Cited by
Recent insights into the pathogenesis of nonalcoholic fatty liver disease
Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043617 · Cited by 573
Self-citationLiver Regeneration after Hepatectomy and Partial Liver Transplantation
Yagi, S., Hirata, M., Miyachi, Y., & Uemoto, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218414 · Cited by 192
“LPS, which is found in the outer membrane of Gram-negative bacteria and is a member of pathogen-associated molecular patterns (PAMPs), is recognized by pattern recognition receptors and elicits innate immunity [25].”
Background
Metadata
- Authors
- Arab, J. P., Martin-Mateos, R. M., & Shah, V. H.
- Venue
- Hepatology International
- Published
- 2017-05-26
- Volume
- 12
- Issue
- S1
- Pages
- 24-33
- ISSN
- 1936-0533 (ISSN-L)
- 1936-0541
- OpenAlex
- W2619133117
- Cited by
- 227
- References
- 48
- FWCI
- 7.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.